Skip to content

Longterm Postoperative Analgesia, Intravenous Lidocaine Infusion

Effect of Intravenous Lidocaine Infusion on Long Term Postoperative Pain After Spinal Fusion Surgery

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03030560
Acronym
Lidocaine
Enrollment
40
Registered
2017-01-25
Start date
2015-04-30
Completion date
2016-12-31
Last updated
2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Brief summary

Spinal fusion is a painful surgery, and control of postoperative pain is difficult. Several studies have indicated that appropriate pain treatment protocols reduce postoperative morbidity, improve the results of the surgery, and decrease hospital costs

Detailed description

Forty four patients were randomly allocated into two groups of equal size to receive either lidocaine infusion (Lidocaine group) or 0.9% sodium chloride infusion (Control group). Randomization: was performed using Lidocaine group and Control group registers, which was placed in sealed envelopes prior to study initiation and opened prior to anesthesia by a physician who prepared the intravenous solution and identified it with the patient number, according to the envelope drawn. The solution was handed to another physician, blind to the prepared solutions' content, who was responsible for the anesthesia. The solution volume was equal. The responsible investigator was remained blind to the chosen group until the end of the study.

Interventions

DRUGLidocaine

patients (n = 20) will receive a loading dose of lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia, then the lidocaine infusion started at a rate of 3 mg ̸ kg/h, and continued until the end of the operation.

patients (n = 20) will receive an equal volume of 0.9% saline (both the loading and the infusion), the infusion will be initiated at the time of induction of anesthesia and continued until the end of the operation.

Sponsors

Abdelrady S Ibrahim, MD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Investigator)

Masking description

Double Blind

Eligibility

Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Age \> 18 years American Society of Anesthesiologists 1-3 status Patients undergoing spinal fusion or fixation

Exclusion criteria

1. Previous spinal fusion surgery. 2. Morbid obesity (BMI \> 40) 3. Diagnosis of spinal metastatic cancer 4. Allergy to an amide local anesthetic or morphine sulfate 5. History of renal dysfunction, liver dysfunction or congestive heart failure 6. History of substance abuse disorder. 7. Chronic opioid use.

Design outcomes

Primary

MeasureTime frameDescription
numerical rating scale (NRS), pain score.Postoperative 3 monthsPostoperative numerical rating scale (NRS), pain score.

Secondary

MeasureTime frameDescription
opioid consumption.Postoperative 24 hPostoperative opioid consumption.
Serum cortisol.Postoperative 24 hSerum cortisol level.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026